24th Annual Scientific and Clinical Congress

Register Here

DISCLOSURE INFORMATION

WEDNESDAY, MAY 13

6:30 am - 6:30 pm Attendee Registration
12:30 pm - 6:30 pm CME Station Hours
8:00 am - 12:00 pm SPECIAL SESSION I
 

W11: Hot Topics in Thyroid Practice

Chair: Hossein Gharib, MD

Room: 101 DE
CME Code: 6135

 

W21: Diabetes Technology Update for Your Practice
Chair: George Grunberger, MD

Room: 102 AB
CME Code: 5096
 

W31: DXA for the Practicing Endocrinologist: What Every Clinician Needs to Know
Chair: Susan E. Williams, MD

Room: 101 B
CME Code: 7124
 

W41: Leadership Forum
Co-Chairs: Howard M. Lando, MD & Anne L. Leddy, MD
Speakers: Tara Hickey & Eric Martin

  • What Leadership Role Can We Play as Champions for Clinical Endocrinologists?
  • What is the Nature of Leadership Work Required for Example to Strengthen Membership and improve the Chapter Effectiveness?
  • What Personal Adaptations May be Required so That We Can More Effectively Lead Consequential Change?

Room: 101 A
CME Code: 1606

1:00 pm - 5:00 pm SPECIAL SESSION II
 

W12: The AACE Module and Tool Kit for Obesity Medicine
Chair: W. Timothy Garvey, MD

Room: 101 B
CME Code: 3467
 

W22: Challenging Topics in Pituitary and Adrenal Disorders
Co-Chairs: Richard J. Auchus, MD & Laurence Katznelson, MD

Room: 101 DE
CME Code: 8382
 

W32: 2015 Diabetes Update
Co-Chairs: Vivian A. Fonseca, MD & Etie S. Moghissi, MD

Room: 102 AB
CME Code: 2035
 

W42: Endocrinology in the Real World
Co-Chairs: Bill Law, Jr., MD & Katherine A. Roberts, MD

Room: 101 A
CME Code: 1122
1:00 pm - 5:30 pm

W52: AACE Maintenance of Certification and Mini-Board Review Course
Chair: Pauline M. Camacho, MD
Speakers: Elise M. Brett, MD, Pauline M. Camacho, MD, & Hossein Gharib, MD

  • To discuss recent updates on the endocrine certification process
  • To discuss ASAP 2014 Thyroid Module
  • To discuss ASAP 2014 Parathyroid & Bone Module

Room: 101 C
CME Code: 7892

5:30 pm - 7:45 pm

WSS1: LDL-C Reduction in the High-Risk Patient: How Low Should We Go?
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 2454

THURSDAY, MAY 14

5:15 am - 7:30 am

TSS1: Overcoming Barriers in Diabetes Management with Individualized Treatment Strategies
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 5456

6:30 am - 6:00 pm Attendee Registration
7:00 am - 6:00 pm CME Station Hours
9:45 am - 2:15 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

TGS1: Bionic Pancreas
Moderator: R. Mack Harrell, MD
Speaker: Edward R. Damiano, MD
Room: BALLROOM A
CME Code: 1348

9:00 am - 9:45 am

TGS2: Neonatal Diabetes: Identification, Initial Treatment, and Transitioning the Parent
Moderator: Yehuda Handelsman, MD
Speaker: Siri A.W. Greeley, MD

Room: BALLROOM A

CME Code: 2924
9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in the Exhibit Hall
11:00 am - 11:45 am

TGS3: Microarchitectural of Bone and its Clinical Relevance
Moderator: Pauline M. Camacho, MD
Speaker: John Paul Bilezikian, MD
Room: BALLROOM A
CME Code: 6520

11:45 am - 12:30 pm

TGS4: The Link Between Retinopathy and VEGF: The Journey from Discovery through Clinical Therapy
Moderator: Sandra L. Weber, MD
Speaker: Michael J. Tolentino, MD
Room: BALLROOM A
CME Code: 1764

12:30 pm - 2:15 pm President’s Welcome Box Lunch in Exhibit Hall
12:45 pm - 1:30 pm

Product Theaters in the Exhibit Hall

12:30 pm - 2:15 pm

Women of Endocrinology Luncheon: If I Knew Then, What I Know Now (non-CME)
Moderator: Etie S. Moghissi, MD
Speaker: Camille Lee, Senior Vice President, Diabetes Marketing for Novo Nordisk Inc.

2:15 pm - 3:15 pm Meet-the-Experts
 

SESSION I

 

T11: Of Hispanics and Metabolism: Understanding the Risk for Diabetes
Moderator: Donald A. Bergman, MD
Speaker: Jaime A. Davidson, MD
Room: 101 B
CME Code: 2502

 

T21: Testosterone Use: When and How; Testosterone Treatment in Young Males
Moderator: Elise M. Brett, MD
Speaker: Paul Turek, MD
Room: 104 ABC
CME Code: 4276

 

T31: Practicalities in the Use of Pharmacologic Agents
Moderator: Felice A. Caldarella, MD
Speaker: Caroline Apovian, MD
Room: 101 A
CME Code: 4366

 

T41: Thyroid Ultrasound Images
Moderator: Mark A. Lupo, MD
Speaker: Robert A. Levine, MD
Room: 103 ABC
CME Code: 3031

 

T51: Controversies in Osteoporosis Management
Moderator: Daniel L. Hurley, MD
Speaker: Felicia Cosman, MD
Room: 101 CDE
CME Code: 2749

 

T61: (Point/Counterpoint) Subclinical Hypothyroidism: Treat or Not
Moderator: Peter A. Singer, MD
Speaker Point: Paul W. Ladenson, MD
Speaker Counter: Jeffrey R. Garber, MD
Room: 104 DE
CME Code: 2533

 

T71: (Case Review) Challenging Lipid Cases
Moderator: David S. H. Bell, MD
Speaker: Lisa Tannock, MD
Room: 102 AB
CME Code: 3370

3:15 pm - 3:30 pm Coffee Break
3:30 pm - 4:30 pm

Meet-the-Expert

 

SESSION II

 

T12: Emerging Therapies and Technologies for the Treatment of Diabetes
Moderator: S. Sethu K. Reddy, MD
Speaker: Irl B. Hirsch, MD
Room: 104 ABC
CME Code: 9140

 

T22: Update on PCKS9 Inhibitors and New Therapies
Moderator: M. Kathleen Figaro, MD
Speaker: Evan A. Stein, MD
Room: 101 CDE
CME Code: 3961

 

T32: Challenges in Management of the Endocrine Patient: Transition of Care from Pediatric to Adult Endocrinology
Moderator: Rajib Bhattacharya, MD
Speaker: A. Jay Cohen, MD
Room: 101 A
CME Code: 8484

 

T42: The Nutritional Prevention and Reversal of Cardiovascular Disease-Fact or Fiction?
Moderator: Chris K. Guerin, MD
Speaker: Caldwell B. Esselstyn, Jr., MD
Room: 102 AB
CME Code: 5611

 

T52: The Mind’s Role in Obesity
Moderator: Michael A. Bush, MD
Speaker: Joshua P. Thaler, MD
Room: 104 DE
CME Code: 3053

 

T62: Ectopic ACTH: Diagnosis and Treatments
Moderator: Janet B. McGill, MD
Speaker: Maria Fleseriu, MD
Room: 101 B
CME Code: 2300

 

T72: (Case Review) Update on Pheochromocytoma and Paraganglioma: Implications for Clinical Practice
Moderator: Rachel Pessah-Pollack, MD
Speaker: Karel Pacak, MD
Room: 103 ABC
CME Code: 8408

4:45 pm - 5:45 pm

Meet-the-Experts
SESSION III

 

T13: Diabetes Transition from Pediatrics to Adulthood
Moderator: Dace L. Trence, MD
Speaker: Jennifer Raymond, MD
Room: 102 AB
CME Code: 6174

 

T23: Statin Intolerance: Statin Side-Effects?
Moderator: Richard A. Haas, MD
Speaker: Lisa Tannock, MD
Room: 101 CDE
CME Code: 4043

 

T33: Late-Effects in the Emerging Population of Childhood Cancer Survivors
Moderator: Vin Tangpricha, MD
Speaker: Sripriya Raman, MD
Room: 101 A
CME Code: 9536

 

T43: Ectopic ACTH: Diagnosis and Treatments
Moderator: Janet B. McGill, MD
Speaker: Maria Fleseriu, MD
Room: 101 B
CME Code: 1816

 

T53: Thyroid Ultrasound Images
Moderator: Mark A. Lupo, MD
Speaker: Robert A. Levine, MD
Room: 103 ABC
CME Code: 1868

 

T63: The Mind’s Role in Obesity
Moderator: Michael A. Bush, MD
Speaker: Joshua P. Thaler, MD
Room: 104 DE
CME Code: 1352

 

T73: (Case Review) Challenging Thyroid Cases
Moderator: Robert S. Zimmerman, MD
Speakers: Paul W. Ladenson, MD & Susan J. Mandel, MD
Room: 104 ABC
CME Code: 5848

6:00 pm - 7:00 pm

Chapter & International Receptions

7:30 pm - 9:45 pm

TSS3: Paradigm Shifts in Hypoparathyroidism: How New Insights in Epidemiology and Treatment are Changing the Standard of Care
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 8313

7:30 pm - 9:45 pm

TSS4: Combination Therapy in Type 2 Diabetes Management: Charting Courses for Success
Room: Omni Nashville - Legends Ballroom EFG
CME Code: 4711

FRIDAY, MAY 15

5:15 am - 7:30 am

FSS1: Prevention and Management of Diabetic Retinopathy and Related Eye Disorders: Clarifying the Endocrinologist's Role
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 4117

5:15 am - 7:30 am

FSS2: Applying the Fundamentals of Insulin Physiology to Modernize Exogenous Insulin Therapy: An Expert Panel Exchange and Interactive Town Hall Discussion
Room: Omni Nashville - Legends Ballroom EFG
CME Code: 3879

7:30 am - 5:30 pm

Attendee Registration

7:30 am - 6: 30 pm CME Station Hours
9:45 am - 2:15 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

FGS1: Molecular Drivers for Fat Genesis and their Roles in Diabetes and Obesity
Moderator: Daniel Einhorn, MD
Speaker: Ronald Evans, PhD
Room: BALLROOM A
CME Code: 9031

9:00 am - 9:45 am

FGS2: Short-Term and Long-Term Impacts of Genetic Discovery on the Practice of Endocrinology
Moderator: Robert Rapaport, MD
Speaker: Joel Hirschhorn, MD
Room: BALLROOM A
CME Code: 6570

9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in Exhibit Hall
11:00 am - 12:30 pm Mini Plenary Sessions
 

FGS3: Transcultural Endocrinology Symposium
Chair/Moderator: Jeffrey I. Mechanick, MD

Room: 101 CDE
CME Code: 6411
11:00 am - 11:45 am

FGS4: Oral Poster Presentations
Moderators: Edward S. Horton, MD & David S. Lieb, MD
Room: 103 ABC
CME Code: 1482

 

FGS5: Thyroid: The Year in Review
Moderator: Peter A. Singer, MD
Speaker: Susan J. Mandel, MD
Room: 104 ABC
CME Code: 2044

11:45 am - 12: 30 pm

FGS6: Late Breaking Clinical Trials (non-CME)
Moderators: Alan J. Garber, MD, Janet B. McGill, MD, & Vin Tangpricha, MD
Room: 104 ABC

 

FGS7: Oral Poster Presentations
Moderators: Edward S. Horton, MD & David C. Lieb, MD
Room: 103 ABC
CME Code: 9498

12:30 pm - 2:15 pm Exhibit Hall Break
12:45 pm - 1:30 pm Product Theaters in Exhibit Hall
2:15 pm - 5:00pm In-Depth Symposia
 

F11: Transition from Childhood to Adulthood
Chair: Robert Rapaport, MD

Room: 101 A
CME Code: 9762
 

F21: Advances in Thyroid Cancer
Chair: Hossein Gharib, MD

Room: 104 ABC
CME Code: 7689
 

F31: Updates on Osteoporosis and Metabolic Bone Disease
Chair: Pauline M. Camacho, MD

Room: 101 CDE
CME Code: 5982
 

F41: Assessing the Benefits and Risks of Testosterone Therapy in Men and Women
Co-Chairs: Paresh Dandona, MD & Neil F. Goodman, MD

Room: 104 DE
CME Code: 7112

 

F51: Novel Therapeutic Approaches to Type 2 Diabetes and Complications
Chair: Robert R. Henry, MD

Room: 103 ABC
CME Code: 9927

 

F61: Lipid Guidelines: Can We Identify the Risk, but Not the Numbers?
Chair: Kathleen L. Wyne, MD

Room: 102 AB
CME Code: 4819

 

F71: AACE/SMNE Pan American Symposia: Lifestyle, Metabolic Disorders and Cancer
Co-Chairs: Myriam Allende-Vigo, MD

Room: 101 B
CME Code: 6499

5:00 pm - 6:30 pm Exhibit Hall Wine & Cheese Reception
7:00 pm - 9:15 pm

FSS3: Continuous Coverage and Clinical Application of Real-Time CGM: Pathway to Improved Outcomes and Reduced Cost
Room: Omni Nashville - Legends Ballroom ABC
CME Code: 7276

7:00 pm - 9:15 pm

FSS4: Managing Obesity in 2015: Setting the Framework and Assessing All of the Options
Room: Omni Nashville - Legends Ballroom EFG
CME Code: 6985

SATURDAY, MAY 16

7:30 am - 5:00 pm Attendee Registration
7:30 am - 6:00 pm CME Station Hours
9:45 am - 1:00 pm Exhibit Hall Hours
8:00 am - 8:15 am General Session Announcements
8:15 am - 9:00 am

SGS1: The Three Pathways of Translational Research: Diabetes and a Personal Experience
Moderator: Jeffrey I. Mechanick, MD
Speaker: Valentin Fuster, MD
Room: BALLROOM A
CME Code: 6637

9:00 am - 9:45 am

SGS2: Deletions and Mutations in Growth Hormone- Receptor (Laron Syndrome): Genetic, Biological, and Clinical Aspects
Moderator: Jaime A. Davidson, MD
Speaker: Zvi Laron, MD
Room: BALLROOM A
CME Code: 9226

9:45 am - 11:00 am Exhibit Hall Coffee Break
10:00 am - 10:45 am Product Theaters in Exhibit Hall
11:00 am - 11:45 am

SGS3: Metformin: Its Non-Glycemic Effects and Cardiovascular Risk Reduction
Moderator: Anne L. Leddy, MD
Speaker: John M. Miles, MD
Room: BALLROOM A
CME Code: 5263

11:45 am - 12:30 pm

SGS4: Disordered Growth Hormone Secretion in HIV: Mechanisms and Novel Therapeutic Strategies
Moderator: Felice A. Caldarella, MD
Speaker: Steven K. Grinspoon, MD
Room: BALLROOM A
CME Code: 6442

12:30 pm - 2:15 pm AACE Annual Business Meeting Luncheon
2:15 pm - 3:15 pm

Meet-the-Expert
SESSION I

 

S11: Year in Diabetes
Moderator: Etie S. Moghissi, MD
Speaker: Claresa S. Levetan, MD
Room: 104 ABC
CME Code: 3747

 

S21: FGF: New Guy on the Scene
Moderator: Sunil Wimalawansa, MD
Speaker: Bryan Kestenbaum, MD
Room: 101 A
CME Code: 4062

 

S31: Neurohumoral Syndromes
Moderator: Derek LeRoith, MD
Speaker: Aaron I. Vinik, MD
Room: 101 B
CME Code: 1351

 

S41: Hyperandrogenic Anovulation
Moderator: W. Reid Litchfield, MD
Speaker: Margaret E. Wierman, MD
Room: 103 ABC
CME Code: 8295

 

S51: The Year in Pituitary Disease
Moderator: Ved V. Gossain, MD
Speaker: Mark E. Molitch, MD
Room: 101 CDE
CME Code: 5747

 

S61: (Point/Counterpoint) To Use or Not Molecular Markers
Moderator: Jonathan D. Leffert, MD
Speaker Point: Bryan McIver, MD
Speaker Counter: Mark A. Lupo, MD
Room: 102 AB
CME Code: 4172

 

S71: (Case Review) Thyroid Cases: Weird and the Not So Unusual
Moderator: Farhad Zangeneh, MD
Speaker: Jeffrey R. Garber, MD
Room: 104 DE
CME Code: 4888

3:15 pm - 3:30 pm Coffee Break
3:30 pm - 4:30 pm

Meet-the-Experts
SESSION II

 

S12: Update on the Impact of Sleep Disturbances in Metabolic Disorders
Moderator: Joseph Aloi, MD
Speaker: Eve Van Cauter, MD
Room: 101 CDE
CME Code: 2049

 

S22: ICD-10
Moderator: Katherine A. Roberts, MD
Speaker: Todd W. Frieze, MD
Room: 104 DE
CME Code: 7338

 

S32: Lipidystrophy
Moderator: Felice A. Caldarella, MD
Speaker: Savitha Subramanian, MD
Room: 102 AB
CME Code: 9000

 

S42: PCOS in Adolescent Girls: Diagnosis and Management
Moderator: Sripriya Raman, MD
Speaker: Selma F. Witchel, MD
Room: 104 ABC
CME Code: 7621

 

S52: Treatment of Progressive Thyroid Cancer
Moderator: Gregory Randolph, MD
Speaker: Steven I. Sherman, MD
Room: 103 ABC
CME Code: 5732

 

S62: Neurohumoral Syndromes
Moderator: Derek LeRoith, MD
Speaker: Aaron I. Vinik, MD
Room: 101 B
CME Code: 2930

 

S72: Preventing Type 2 Diabetes in Latino Youth: translational Science to Clinical Relevance
Moderator: Craig Wierum, MD
Speaker: Gabriel Q. Shaibi, MD
Room: 101 A
CME Code: 5415

4:45 pm- 5:45 pm SESSION III
  Meet-the-Experts
 

S13: Normocalcemic Hyperparathyroidism
Moderator: Gary W. Edelson, MD
Speaker: Shonni J. Silverberg, MD
Room: 104 ABC
CME Code: 3027

 

S23: Endocrine Jeopardy
Moderator: Ricardo Correa, MD
Speaker: Cheryl Rosenfeld, MD
Room: 104 DE
CME Code: 9598

 

S33: Update on the Impact of Sleep Disturbances in Metabolic Disorders
Moderator: Joseph Aloi, MD
Speaker: Eve Van Cauter, MD
Room: 101 CDE
CME Code: 2554

 

S43: Subclinical Cushing’s
Moderator: Donald W. Richardson, MD
Speaker: John D. Carmichael, MD
Room: 102 AB
CME Code: 5477

 

S53: Neutroceuticals
Moderator: Shashank R. Joshi, MD
Speaker: Kenneth D. Burman, MD
Room: 101 A
CME Code: 7915

 

S63: Treatment of Progressive Thyroid Cancer
Moderator: Gregory Randolph, MD
Speaker: Steven I. Sherman, MD
Room: 103 ABC
CME Code: 9199

 

S73: (Point/Counterpoint) Data on Ethnic Disparities in Diabetes Prevalence
Moderator: Gary A. Trager, MD
Speaker Point: Elizabeth Selvin, MD
Speaker Counter: Samuel Dagogo-Jack, MD
Room: 101 B
CME Code: 7635

6:30 pm ACE Convocation
7:30 pm President’s Gala

SUNDAY, MAY 17

7:00 am - 11:30 am Attendee Registration
7:30 am - 12:00 pm CME Station Hours
7:00 am - 8:00 am

Breakfast
Room: BALLROOM A

8:00 am - 8:15 am

General Session Announcements

8:00 am - 11:00 am

Oral Presentations on Planning Research in Diabetes (PRIDE) F(non-CME)

Room: 108
8:15 am - 9:00 am

SGS5: AACE/AAES Joint Review of Cases on Hyperparathyroidism

Moderator: Nancy D. Perrier, MD Speakers: Mira Milas, MD & Shonni J. Silverberg, MD
Room: BALLROOM A
CME Code: 5183

9:15 am - 10:00 am

SGS6: AACE/AAES Joint Review of Cases on Thyroid Cancer Management

Moderator: Carmen C. Solorzano, MD
Speakers: Gregory Randolph, MD & R. Michael Tuttle, MD
Room: BALLROOM A
CME Code: 9932

10:15 am - 11:00 am

SGS7: AACE/AAES Joint Review of Cases on Adrenal Nodules

Moderator: Gerard Doherty, MD
Speakers: Clive S. Grant, MD & Gary D. Hammer, MD
Room: BALLROOM A
CME Code: 5590

11:00 am - 11:15 am Final Announcements; Adjournment

DISCLOSURE INFORMATION

Declaration of Disclosure and Conflicts of Interest

It is the policy of AACE to ensure balance, independence, objectivity and scientific rigor in all of its CME activities.  Presentation content may include discussion of an unlabeled or an investigational use of a product.  AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature. 

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest.  AACE requires speakers, faculty, CME Committee and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation and educational materials used as basis for content, and appropriateness of patient care recommendations. 

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments.  Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence. 

AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

CME Accreditation Committee Disclosures

Dr. Myriam Allende-Vigo reports that she has received advisor honoraria from Merck & Co., Inc. and speaker honoraria from Abbott Laboratories and Janssen Pharmaceuticals, Inc.

Dr. David S.H. Bell reports that he has received consultant and speaker honoraria from AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk A/S, Salix Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Dr. Felice A. Caldarella reports that he has received speaker honoraria from speaker honoraria from Novo Nordisk A/S, Salix, and Takeda Pharmaceutical Company Limited.

Dr. Ricardo Correa reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Stephen R. Crespin reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Martin Grajower reports that he has received speaker honoraria from Bristol-Myers Squibb Company, Novo Nordisk A/S, and Vivus, Inc.

Dr. Virginia A. LiVolsi reports that she has received histopathology consultant honoraria from Veracyte, Inc.

Dr. Dorothy S. Martinez reports that she does not have any relevant financial relationships with any commercial interests.

Dr. Robert McCauley reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Fernando Ovalle reports that he has received consultant/research fees from Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Inc., Novo Nordisk A/S, and sanofi-aventis U.S. LLC.

Dr. Miguel Pinto reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Andrew R. Reikes reports that his spouse is an employee and stockholder of GlaxoSmithKline plc.

Dr. Kenneth Snow reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Peter Thule reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Joseph M. Tibaldi reports that he has received speaker honoraria from Daiichi-Sankyo company, Limited, Janssen Pharmaceuticals, and Merck & Co., Inc., and speaker/consultant honoraria from Novo Nordisk A/S.

Dr. Dace L. Trence reports that she is a stockholder of Medtronic, Inc. and  sanofi-aventis U.S. LLC. 

Dr. Jeff Unger reports that he has received speaker honoraria from Janssen Global Services, LLC, Novo Nordisk A/S, and Valeritas, Inc.

Program Committee Disclosures

*Dr. Sandra Weber reports that she has received research grant support for her role as Principal Investigator from National Institutes of Health, Novo Nordisk A/S, and sanofi-aventis US LLC. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Weber has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Felice A. Caldarella reports that he has received speaker honoraria from Novo Nordisk A/S, Salix, and Takeda Pharmaceutical Company Limited. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Caldarella has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Anne Leddy reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Leddy has no identified conflicts of interest.

*Dr. Yehuda Handelsman reports that he has received research grant support, consultant honoraria, and fees from Boehringer Ingelheim GmbH, GlaxoSmithKline plc, and  Novo Nordisk A/S; research grant support and consulting fees from Amgen Inc., Gilead, Merck & Co., and sanofi-aventis U.S. LLC; research grant support from Intarcia,  Lexicon, and Takeda Pharmaceutical Company Limited; consultant/speaker fees from Amarin Corp., Amylin Pharmaceuticals,  Janssen Global Services, LLC, and Vivus Inc; and consultant fees from Halozyme Therapeutics. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Handelsman has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. R. Mack Harrell reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product.  Dr. Harrell has no identified conflicts of interest.

*Dr. Timothy Bailey reports that he has received speaker and consultant honoraria and research support from Novo Nordisk A/S; consultant honoraria and research support from Bayer AG, Becton Dickinson and Company, Medtronic, Inc., and Sanofi; and research support from Abbott Laboratories, Acon Laboratories, Inc., Alere, Animas Corporation, Cebix, Inc., Bristol-Myers Squibb Company, Dexcom, Inc., Eli Lilly and Company, GlaxoSmithKline, Halozyme, Inc., Insulet Corporation, Lifescan, Inc., Mannkind Corporation, Merck & Co., Inc., Orexigen Therapeutics, Inc., and Tandem Diabetes Care. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bailey has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Pauline M. Camacho reports that she has received stock from Abbott /Abbvie Inc., research grant support for her role as PI and advisory board member fees from Amgen Inc., research grant support for her role as PI from Eli Lilly and Company, and advisory board fees from Intarcia Therapeutics, Inc. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Camacho has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Gerard M. Doherty reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Doherty has no identified conflicts of interest.

*Dr. M. Kathleen Figaro reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Figaro has no identified conflicts of interest.

*Dr. Chris K. Guerin reports that he has received speaker honoraria from Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Guerin has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Robert Henry reports that he has received consultant honoraria from Shionogi & Co., Ltd. and Isis Pharmaceuticals, Inc.; scientific advisory board honoraria from Merck & Co, Inc., Novo Nordisk A/S, Vivus Inc., and Valeritas, Inc.; scientific advisory board/consultant honoraria from AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH,  ClinMet, and Gilead; scientific advisory board honoraria and research grant support from Johnson & Johnson Services, Inc./Janssen Global Services, LLC, Intarcia Therapeutics, Inc., Elcelyx, and sanofi-aventis U.S. LLC. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Henry has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Edward S. Horton reports that he has received advisory board honoraria from Axon Drugs Private Limited, global advisory board honoraria from Amgen Inc., speaker honoraria from Merck & Co., Inc., and Data Safety Monitoring Board honoraria from Takeda Pharmaceutical Company Limited, and Theracos, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Horton an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Daniel Hurley reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hurley has no identified conflicts of interest.

*Dr. Jonathan Leffert reports that he has received speaker honoraria from Abbott Laboratories and research grant support for his role as an investigator from AbbVie, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Merck & Co., Inc., and Sanofi. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Leffert has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Mira Milas reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Milas has no identified conflicts of interest.

*Dr. Nancy Perrier reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Perrier has no identified conflicts of interest.

*Dr. Rachel Pessah-Pollack reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Pessah-Pollack has no identified conflicts of interest.

*Dr. Sripriya Raman reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Raman has no identified conflicts of interest.

*Dr. Gregory Randolph reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Randolph has no identified conflicts of interest.

*Dr. Robert Rapaport reports that he has received global advisory board honoraria from Novo Nordisk A/S and advisory board honoraria from Sandoz. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Rapaport has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Peter A. Singer reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Singer has no identified conflicts of interest.

*Dr. Carmen Solorzano reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Solorzano has no identified conflicts of interest.

*Dr. Vin Tangpricha reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tangpricha has no identified conflicts of interest.

*Dr. Dace Trence reports that she is a stockholder of Medtronic, Inc. and  sanofi-aventis U.S. LLC. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Trence has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Aaron I. Vinik reports that he has received speaker honoraria and consultant fees from Pamlab, Inc., consultant fees from Isis Pharmaceuticals, Inc. and NeuroMetrix, Inc., and research grant support for his role as Principal Investigator from Impeto Medical, Intarcia Therapeutics, Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi, ViroMed Laboratories, Inc., and VeroScience. He also reports that his presentation will include discussion of investigational or unlabeled uses of alpha lipoic for somatic and autonomic neuropathy; topiramate for painful and small fiber neuropathy; and methylcobolamin, methylfolate and pyridoxal phosphate for symptomatic neuropathy and patients on metformin with low B12 levels <450 pg.  Dr. Vinik has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Craig Wierum reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH/Eli Lilly and Company, and Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Wierum has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Susan Williams reports that she has received speaker and consultant honoraria from Johnson & Johnson Services, Inc. and scientific advisory board member honoraria from NPS Pharmaceuticals stockholder of Medtronic, Inc. and  sanofi-aventis U.S. LLC. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Williams has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Kathleen Wyne reports that she has received speaker honoraria from AstraZeneca, GlaxoSmithKline plc, Novo Nordisk A/S, and Salix. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Wyne has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Farhad Zangeneh reports that he has received speaker honoraria from Arbor Pharmaceuticals, LLC, AstraZeneca, Eisai Inc., GlaxoSmithKline, Novo Nordisk A/S, and Takeda Pharmaceutical Company Limited; and speaker and consultant honoraria from Boehringer Ingelheim GmbH/Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Santarus, Inc. /Salix Pharmaceuticals, Inc., and Vivus, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Zangeneh has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Robert Zimmerman reports that he has received speaker honoraria and research grant support from Merck & Co., Inc. and research grant support from Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Zimmerman has no identified conflicts of interest.

* denotes individual is both a member of the Program Committee and the Faculty

Faculty Disclosures

Dr. Myriam Z. Allende-Vigo reports that she has received advisor honoraria from Merck & Co., Inc. and speaker honoraria from Abbott Laboratories and Janssen Pharmaceuticals, Inc. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Allende-Vigo has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Joseph Aloi reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Aloi has no identified conflicts of interest.

Dr. Caroline Apovian reports that she has received Advisory Board consultant fees from Amylin Pharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co., Inc., MYOS Corporation, Novo Nordisk A/S, Nutrisystem, Inc., Sanofi, and Zafgen; research funds for her role as Principal Investigator from Aspire Bariatrics and GI Dynamics, Inc.; Advisory Board consultant fees and research funds for her role as Principal Investigator from Orexigen Therapeutics, Inc.; and speaker’s bureau honoraria from Takeda Pharmaceutical Company Limited. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Apovian has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Richard J. Auchus reports that he has received contracted research support for his role as Principal Investigator from Cortendo, Neurocrine Biosciences, Inc. and Novartis AG; contracted research support for his roles as an investigator from Atterocor; and consultant fees from Corcept Therapeutics, ISIS Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Tokai Pharmaceuticals, and Viamet Pharmaceuticals, Inc. He also reports that his presentation will include discussion of investigational or unlabeled uses of abiraterone acetate, NBI-77860, and modified-release hydrocortisone for treatment of congenital adrenal hyperplasia. Dr. Auchus has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Rajib Bhattarcharya reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bhattarcharya has no identified conflicts of interest.

Dr. David S.H. Bell reports that he has received consultant and speaker honoraria from AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk A/S, Salix Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bell has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Donald A. Bergman reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bergman has no identified conflicts of interest.

Dr. Antonio Bianco reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bianco has no identified conflicts of interest.

Dr. John Bilezikian reports that he has received consultant fees from Amgen Inc., Merck & Co., Inc., NPS, and Radius Health, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bilezikian has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Bruce Bode reports that he has received research support to his employer for his role as Principal Investigator from Abbott Laboratories, Dexcom, Inc., Halozyme, Inc., and Mannkind Corporation, speaker honoraria, advisory board fees and research support for his role as Principal Investigator from Janssen Pharmaceuticals, Inc., speaker honoraria from AstraZeneca, Eli Lilly and Company, and Merck & Co., Inc.; and speaker honoraria, consultant fees, and research support to his employer for his role as Principal Investigator from Medtronic, Inc., Novo Nordisk A/S, and Sanofi. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bode has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Elise Brett reports that her spouse is an employee of Novo Nordisk A/S. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Brett has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Eliot Brinton reports that he has received speaker and consultant honoraria from Aegerion Pharmaceuticals, Inc., Atherotech, AstraZeneca, Kowa Pharmaceuticals America, Inc., and Janssen Pharmaceuticals, Inc.; consultant and research honoraria from Arisaph Pharmaceuticals, Inc., and speaker, consultant, and research honoraria from Amarin Corp. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of alirocumab, evolucumab, and bococizumab for cholesterol lowering. Dr. Brinton has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Susan Broy reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Broy has no identified conflicts of interest.

Dr. Kenneth Burman reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Burman has no identified conflicts of interest.

Dr. John Buse reports that he has received consultant fees from Dance Biopharm, Elcelyx Therapeutics, Inc., LipoScience, Inc., Metavention, and TransTech Pharma, LLC; research grant support from Andromeda Pharmaceuticals, Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline, Halozyme, Inc., Intarcia Therapeutics, Johnson & Johnson Services, Inc., Lexicon Pharmaceuticals, Inc., MacroGenics, Inc., Medtronic Minimed, Inc., Osiris Therapeutics, Inc., Pfizer, Inc., Sanofi, Takeda Pharmcaceutical Company Limited, and Tolerx, Inc.; consultant fees and research grant support from Amylin Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GI Dynamics, Inc., Hoffman-LaRoche, Inc., Merck & Co., Inc., Novo Nordisk A/S, and Orexigen Therapeutics, Inc.; and stockholder options and consultant fees from PhaseBio Pharmaceuticals, Inc. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of various products for new insulins, new insulin-GLP-1 formulations, and CV effects of incretin drugs. Dr. Buse has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Michael Bush reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, and Vivus, Inc., and consultant honoraria from Janssen Pharmaceuticals, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bush has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. John Carmichael reports that he has received Advisory Board honoraria from Pfizer, Inc. and Advisory Board honoraria and manuscript and research support for his role as an investigator from Novartis AG. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Carmichael has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. A. Jay Cohen reports that he has received speaker honoraria and research grant support for research trials from Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi, and Janssen Pharmaceuticals, Inc.; speaker honoraria from AbbVie, Inc., AstraZeneca, and Boehringer Ingelheim; and speaker and Advisory Board honoraria from Corcept Therapeutics and Endo Pharmaceuticals, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Cohen has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ricardo Correa reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Correa has no identified conflicts of interest.

Dr. Felicia Cosman reports that she has received speaker, advisor, and consultant honoraria from Amgen, Inc. and Eli Lilly and Company; advisor and consultant honoraria from Merck & Co., Inc.; and advisor honoraria from Radius Health, Inc. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of PTH combination s/ sequences with anti-resorptive agents for severe osteoporosis. Dr. Cosman has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Samuel Dagogo-Jack reports that he has received consultant honoraria and research contract support for his role as Principal Investigator from AstraZeneca, Boehringer Ingelheim GmbH, and Novo Nordisk A/S; and consultant honoraria from Merck & Co., Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Dagogo-Jack has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. David D’Alessio reports that he has received consultant fees from Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., and Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. D’Alessio has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Edward Damiano reports that he has received speaker honoraria from Eli Lilly and Company, Dexcom, Inc., and Tandem Diabetes Care. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of glucagon, insulin pump, and CGM for use in bionic pancreas. Dr. Damiano has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Paresh Dandona reports that he has received research grant support from Abbott Laboratories, National Institutes of Health, Daiichi Sankyo Company, Limited, Allergan, Inc., Conjuchem, LLC, Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Proctor & Gamble, Bristol-Myers Squibb Company, Solvay, Takeda Pharmaceutical Company Limited, ToleRx, Inc., and Transition Therapeutics, Inc.; speaker honoraria from Eli Lilly and Company and Merck & Co., Inc.; speaker and consultant honoraria from AstraZeneca, AbbVie, Inc., and Boehringer Ingelheim GmbH; research grant support and speaker honoraria from Sanofi; and research grant support and speaker and consultant honoraria from GlaxoSmithKline and Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Dandona has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jaime Davidson reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Davidson has no identified conflicts of interest.

Dr. Susan Davis reports that she has received speaker honoraria from Abbott Laboratories and research support to her institution from Lawley Pharmaceuticals Ltd. and Trimel Pharmaceuticals Corporation. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of transdermal testosterone in the treatment of women. Dr. Davis has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ralph DeFronzo reports that he has received speaker and Advisory Board honoraria and research grant support for his role as an investigator from Astra Zeneca; Advisory Board honoraria and research grant support for his role as an investigator from Boehringer Ingelheim GmbH; speaker and Advisory Board honoraria from Novo Nordisk A/S; Advisory Board honoraria from Janssen Pharmaceuticals, Inc. and Lexicon Pharmaceuticals, Inc.; and research grant support for his role as an investigator from Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. DeFronzo has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Sandeep Dhindsa reports that he has received speaker honoraria from AbbVie, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Dhindsa has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jolanta Durski reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will include discussion of any investigational or unlabeled use(s) of iodine 124 in the use of thyroid cancer imaging, F18 dopa and GA-68 Octreotide in the use of medullary thyroid cancer imaging. Dr. Durski has no identified conflicts of interest.

Dr. Gary W. Edelson reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Edelson has no identified conflicts of interest.

Dr. Daniel Einhorn reports that he has received consultant honoraria from Bristol-Myers Squibb/AstraZeneca/Amylin, Halozyme, and Novo Nordisk A/S; research grant support from AstraZeneca, Mannkind Corporation, sanofi-aventis U.S. LLC, and Takeda Pharmaceutical Company Limited; grant support for research, consulting, and speaking from Janssen; stock options for his role as consultant from Freedom Meditech and Glysens; and consultant honoraria and research grant support from Eli Lilly and Company. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Einhorn has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Caldwell Esselstyn, Jr. reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Esselstyn has no identified conflicts of interest.

Dr. Ronald Evans reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Evans has no identified conflicts of interest.

Dr. James Falko reports that he has received speaker and consultant honoraria from Aegerion Pharmaceuticals, Inc., AstraZeneca, and Merck & Co., Inc., consultant honoraria from Kowa Pharmaceuticals America, Inc., and speaker honoraria from Sanofi. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of PCSK9 in hypercholesterolemia. Dr. Falko has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Maria Fleseriu reports that she has received research support to her institution for her role as Principal Investigator from Cortendo; and consultant honoraria and research support to her institution for her role as Principal Investigator from Novartis AG. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of cabergoline, ketoconazole, and metyrapone in the off label use of Cushing’s. Dr. Fleseriu has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Vivian Fonseca reports that he has received research grants to Tulane and consulting/lecture honoraria from Novo Nordisk A/S, sanofi-aventis U.S. LLC, Eli Lilly and Company, and PamLabs LLC, research grants to Tulane from Asahi, Reata Pharmaceuticals Inc., and Halozyme Therapeutics; consultant honoraria from Bristol-Myers Squibb; and consulting/lecture honoraria from GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fonseca has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Todd Frieze reports that he has received speaker honoraria from Abbott Laboratories and Alexion Pharmaceuticals. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Frieze has no identified conflicts of interest.

Dr. Valentin Fuster reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fuster has no identified conflicts of interest.

Dr. Jeffrey Garber reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garber has no identified conflicts of interest.

Dr. W. Timothy Garvey reports that he has received Advisory Board honoraria from Boehringer Ingelheim GmbH, Daiichi-Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., LipoScience, Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, and Vivus, Inc.; research support from Merck & Co., Inc., Sanofi, Weight Watchers International, Inc., Lexicon Pharmaceuticals, Inc., and Pfizer Inc.; and Advisory Board honoraria and research support from AstraZeneca and Eisai Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garvey has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. James Gavin III reports that he has received speaker fees from AstraZeneca and Janssen Pharmaceuticals, Inc.; Advisory Board consultant fees from Abbott Laboratories and Intarcia Therapeutics, Inc.; and speaker fees and consultant honoraria from Boehringer Ingelheim GmbH. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gavin has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Hossein Gharib reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gharib has no identified conflicts of interest.

Dr. J. Michael Gonzalez-Campoy reports that he has received speaker honoraria from AstraZeneca, GlaxoSmithKline plc, Janssen Global Services, LLC, Takeda Pharmaceutical Company, Limited, and Vivus Inc., consultant honoraria from Novo Nordisk A/S and ValenTx, Inc., and speaker honoraria and research funds from Eisai Co., Ltd. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gonzalez-Campoy has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Neil Goodman reports that he has received speaker fees from AbbVie, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Goodman has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ved Gossain reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gossain has no identified conflicts of interest.

Dr. Clive Grant reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Grant has no identified conflicts of interest.

Dr. Siri Greeley reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of glyburide (generic) in monogenic diabetes. Dr. Greeley has no identified conflicts of interest.

Dr. Steven Grinspoon reports that he has received consultant fees from Theratechnologies Inc. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of Tesamorelin as a growth hormone analogue. Dr. Grinspoon has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. George Grunberger reports that he has received speaker honoraria from Boehringer Ingelheim GmbH, Eisai, Janssen Global Services, LLC, Merck & Co., sanofi-aventis U.S. LLC, Salix, Takeda Pharmaceutical Company Limited, Valeritas, and Vivus Inc.; investigator support from Medtronic, Inc., and speaker honoraria and investigator support from AstraZeneca, Eli Lilly and Company, and Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Grunberger has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Scott Grundy reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Grundy has no identified conflicts of interest.

Dr. Osama Hamdy reports that he has received consultant honoraria from Abbott Laboratories and Merck & Co., Inc; and research support from Metagenics, Inc. and NeuroMetrix, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hamdy has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Gary Hammer reports that he has received consultant fees from Corcept Therapeutics, HRA Pharma, Isis Pharmaceuticals, Inc., and OSI Pharmaceuticals, Inc.; consultant stock options from Embera NeuroTherapeutics, Inc. and Orphagen Pharmaceuticals; and stock options for his role as founder and owner of Atterocor. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hammer has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to change the focus of his presentation so that the content is not about products or services of the commercial interest that are the basis of the conflict of interest.

Dr. Bruan Haugen reports that he has received speaker honoraria from Genzyme Corporation and research grant support from Veracyte, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Haugen has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Laszlo Hegedus reports that he has received Board Membership fees from Theraclion; and Board Membership compensation, consultant fees, and research grant support from The Novo Nordisk Foundation. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hegedus has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Ms. Tara Hickey reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Ms. Hickey has no identified conflicts of interest.

 Dr. Irl Hirsch reports that he has received consultant honoraria from Abbott Laboratories and Hoffman-LaRoche, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hirsch has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Joel Hirschhorn reports that he has received research grant support from Pfizer, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hirschhorn has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Peter Jones reports that he has received Advisory Board honoraria from Amgen, Inc. and Sanofi/Regeneron Pharmaceuticals, Inc.; medical Advisory Board honoraria from Atherotech; and scientific Advisory Board and speaker honoraria from Merck & Co., Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Jones has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Shashank Joshi reports that he has received speaker honoraria from Boehringer Ingelheim GmbH, Merck & Co., Inc., Ranbaxy Laboratories Limited, and Sanofi; Advisor honoraria from Franco-Indian Pharmaceuticals Pvt. Ltd. and USV Limited; Advisory Board honoraria from Hoffman-La Roche Inc.; speaker and consultant honoraria from Bayer Zydus Pharma, Johnson & Johnson Services, Inc., and Marico; and Advisory Board and speaker honoraria from Abbott Laboratories, Novartis AG, Novo Nordisk A/S, and Pfizer, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Joshi has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Laurence Katznelson reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Katznelson has no identified conflicts of interest.

Dr. Bryan Kestenbaum reports that he has received consultant honoraria from Keryx Biopharmaceuticals, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Kestenbaum has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Paul Ladenson reports that he has received stock options for his role as an advisor from Expert Appointment and advisor honoraria from Veracyte, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Ladenson has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Howard Lando reports that he has received speaker honoraria from Daiichi Sankyo Company, Limited and Santarus, Inc., stockholder options from Pfizer, Inc. and Proctor & Gamble; and speaker honoraria and stock options from Abbott Laboratories and AbbVie, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lando has no identified conflicts of interest.

Dr. Zvi Laron reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Laron has no identified conflicts of interest.

Dr. Bill Law, Jr. reports that he has received clinical research fees for his role as Principal Investigator from GI Dynamics, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Law has no identified conflicts of interest.

Dr. Derek LeRoith reports that he has received consultant honoraria from AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., and Sanofi. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product.  Dr. LeRoith has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Claresa Levetan reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Levetan has no identified conflicts of interest.

Dr. Robert Levine reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Levine has no identified conflicts of interest.

Dr. Angelo Licata reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Licata has no identified conflicts of interest.

Dr. W. Reid Litchfield reports that he has received speaker honoraria from Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Litchfield has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Mark Lupo reports that he has received speaker honoraria from AbbVie, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lupo has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Susan Mandel reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Mandel has no identified conflicts of interest.

Mr. Eric Martin reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Mr. Martin has no identified conflicts of interest.

Dr. Janet McGill reports that she has received research grant support from Andromeda Biotech Ltd., Novartis AG, and Pfizer, Inc.; speaker honoraria from Abbott Laboratories, AbbVie, Inc., AstraZeneca, Boehringer Ingelheim GmbH/Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Mannkind Corporation, and Merck & Co., Inc.; and research grant support and speaker honoraria from Novo Nordisk A/S and Sanofi. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. McGill has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Bryan McIver reports that he has received speaker honoraria from CBL Path, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. McIver has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jeffrey Mechanick reports that he has received lecture and program development honoraria from Abbott Laboratories. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Mechanick has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Etie Moghissi reports that she has received consultant fees from AstraZeneca, speaker fees from Boehringer Ingelheim GmbH, Janssen Global Services LLC, and Takeda Pharmaceutical Company Limited, and consultant/speaker fees from Novo Nordisk A/S and Merck & Co. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Moghissi has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. John Miles reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Miles has no identified conflicts of interest.

Dr. Mark Molitch reports that he has received consultant honoraria from AbbVie, Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., and Takeda Pharmaceutical Company Limited; research grant support for his role as an investigator from Bayer AG, Corcept Therapeutics, and Ipsen Group; and consultant honoraria and research grant support for his role as an investigator from Novartis AG and Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Molitch has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Yuri Nikiforov reports that he has received consultant fees from Quest Diagnostics. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Nikiforov has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Dan O’Connell reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. O’Connell has no identified conflicts of interest.

Dr. Karel Pacak reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of fluorodopamine, fluorodopa, and fluorothymidine for PET imaging. Dr. Pacak has no identified conflicts of interest.

Dr. Franciso Pasquel reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Pasquel has no identified conflicts of interest.

Dr. Steven Petak reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Petak has no identified conflicts of interest.

Dr. Jennifer Raymond reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Raymond has no identified conflicts of interest.

Dr. Robert Recker reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Recker has no identified conflicts of interest.

Dr. Sethu Reddy reports that he has received speaker honoraria from Merck & Co., Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Reddy has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Thomas Repas reports that he has received research sponsorships for his role as clinical investigator from Amgen, Inc., Hanmi Pharm.Co., Ltd., and Merck & Co., Inc.; and speaker honoraria and research sponsorships for his role as clinical investigator from Novo Nordisk A/S and Sanofi. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Repas has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Donald Richardson reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Richardson has no identified conflicts of interest.

Dr. Katherine Roberts reports that she has received speaker honoraria from Takeda Pharmaceutical Company Limited. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product.  Dr. Roberts has no identified conflicts of interest.

Dr. Clifford Rosen reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Rosen has no identified conflicts of interest.

Dr. Cheryl Rosenfeld reports that she has received consultant fees from Boehringer Ingelheim, GmbH, Becton Dickinson and Company, and Novartis AG; speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH/Eli Lilly and Company, Genzyme Corporation, and Novo Nordisk A/S; consultant fees and speaker honoraria from Eisai Inc., and consultant fees, speaker honoraria, and research grant support for her role as Principal Investigator from Valeritas, Inc. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Rosenfeld has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ron Rosenfeld reports that he has received consultant fees from Ascendis Pharma, Genexine Co Ltd, Novo Nordisk A/S, OPKO Health Inc., Teva Pharmaceutical Industries Ltd., and Versartis, Inc.; and speaker honoraria from Pfizer, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Rosenfeld has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Susan Samson reports that she has received Advisory Board honoraria, research grant support for her role as Principal Investigator, and funding for her role as site Principal Investigator from Novartis AG. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Samson has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Elizabeth Selvin reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Selvin has no identified conflicts of interest.

Dr. Gabriel Shaibi reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Shaibi has no identified conflicts of interest.

Dr. Steven Sherman reports that he has received consultant fees from Bayer AG and Eisai Inc.; consultant fees and honoraria from Exelixis, Inc.; speaker honoraria from Onyx; and speaker honoraria and research support from Genzyme Corporation. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of sunitinib, vadetanib, pazopanib, lenvatinib, and vemurafenib in differentiated thyroid cancer. Dr. Sherman has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Shonni Silverberg reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Silverberg has no identified conflicts of interest.

Dr. Charles Sklar reports that he has received speaker honoraria from Sandoz. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Sklar has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Elisabeth Solis-Perez reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Solis-Perez has no identified conflicts of interest.

Dr. Phyllis Speiser reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of metformin and androgen receptor antagonists in PCOS. Dr. Speiser has no identified conflicts of interest.

Dr. Evan Stein reports that he has received consultant honoraria from Amgen, Inc., Bristol-Myers Squibb Company, Genentech, Inc./Hoffman-La Roche Inc., and Regeneron Pharmaceuticals, Inc./Sanofi. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of evolocumab, alirocumab, and bococizumab as a PCSK9 inhibitor for LDC-C lowering. Dr. Stein has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Savitha Subramanian reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Subramanian has no identified conflicts of interest.

Dr. William Tamborlane reports that he has received received consultant fees from Boehringer Ingelheim GmbH, Halozyme, Inc., Insuline, Janssen Pharmaceuticals, Inc., Medtronic, Inc., Novo Nordisk A/S, Sanofi, and Unomedical a/s. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tamborlane has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Lisa Tannock reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tannock has no identified conflicts of interest.

Dr. Joshua Thaler reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of liraglutide in weight loss. Dr. Thaler has no identified conflicts of interest.

Dr. Michael Tolentino reports that he has received research grant support for his role as Principal Investigator from Allergan, Inc. and Genentech, Inc./Hoffman-La Roche Inc.; consultant honoraria and research grant support for his role as Principal Investigator from Bayer AG; and speaker honoraria and research grant support for his role as Principal Investigator from Regeneron Pharmaceuticals, Inc. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of Avaston in intravitreal injections DME. Dr. Tolentino has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Gary Trager reports that he has received consultant and speaker honoraria from AbbVie, Inc., Amarin Corp., AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Inc., GlaxoSmithKline, Johnson & Johnson Services, Inc., Onyx, Pamlab, Inc., and Warner Chilcott; and consultant and speaker honoraria and grant support for his role as Principal Investigator from Takeda Pharmaceutical Company Limited. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Trager has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Paul Turek reports that he has received Advisory Board stock options from BioQuiddy, Incorporated, Doximity, Inc., Episona, Inc., Fertility Planit, and HealthLoop; officer stock options from MandalMed, Inc.; and founder and officer stock options from Cellarity, IT, LLC. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of clomiphene citrate, human chorionic gonadotropin, and anastrazole/testolactone in male hypogonadism. Dr. Turek has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. R. Michael Tuttle reports that he has received consultant honoraria from Bayer AG/Onyx, Eisai Inc., Genzyme Corporation/Sanofi, Novo Nordisk A/S, and Veracyte, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tuttle has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Eve Van Cauter reports that she has received grant support for her role as Principal Investigator from AstraZeneca and Merck & Co., Inc.; and consultant fees and grant support for her role as Principal Investigator from Koninklijke Philips. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Van Cauter has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Douglas Van Nosrand reports that he has received speaker honoraria from Genzyme Corporation. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Nosrand has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Nelson Watts reports that he has received consultant fees from AbbVie, Inc. and Radius Health, Inc.; research support for clinical trials from NPS Pharmaceuticals; consultant fees and speaker honoraria from Amgen, Inc. and Merck & Co., Inc.; and stock options and royalties for his role as co-founder and director of OsteoDynamics. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of odanacatib, romososumab, and BA058 in the treatment of osteoporosis. Dr. Watts has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to change the focus of his presentation so that the content is not about products or services of the commercial interest that are the basis of the conflict of interest.

Dr. Margaret Wierman reports that she has received research grant support from the Colorado Brain Injury Program; and research grant support for her role as an investigator from Novartis AG, Novo Nordisk A/S, Pfizer, Inc., and Prolor Biotech Inc. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Wierman has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Sumil Wimalawansa reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Wimalawansa has no identified conflicts of interest.

Dr. Selma Witchel reports that she has received consultant fees and honoraria from AbbVie, Inc. and speaker fees from Pfizer, Inc. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of metformin in the treatment of PCOS in adolescent girls. Dr. Witchel has an identified conflict of interest and it has been resolved accordingly.  She has been advised by the AACE CME Accreditation Committee to base her presentation.

Oral Presentation Faculty Disclosures

Dr. Edward S. Horton reports that he has received advisory board honoraria from Axon Drugs Private Limited, global advisory board honoraria from Amgen Inc., speaker honoraria from Merck & Co., Inc., and Data Safety Monitoring Board honoraria from Takeda Pharmaceutical Company Limited, and Theracos, Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Horton an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. David Lieb reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lieb has no identified conflicts of interest.

Dr. Paresh Dandona reports that he has received research grant support from Abbott Laboratories, National Institutes of Health, Daiichi Sankyo Company, Limited, Allergan, Inc., Conjuchem, LLC, Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Proctor & Gamble, Bristol-Myers Squibb Company, Solvay, Takeda Pharmaceutical Company Limited, ToleRx, Inc., and Transition Therapeutics, Inc.; speaker honoraria from Eli Lilly and Company and Merck & Co., Inc.; speaker and consultant honoraria from AstraZeneca, AbbVie, Inc., and Boehringer Ingelheim GmbH; research grant support and speaker honoraria from Sanofi; and research grant support and speaker and consultant honoraria from GlaxoSmithKline and Novo Nordisk A/S. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Dandona has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Kathleen Hands reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hands has no identified conflicts of interest.

Dr. Zdravko Kamenov reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Kamenov has no identified conflicts of interest.

Dr. Rifka Schulman reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will include discussion of investigational or unlabeled use(s) of Pamidronate in CCI Bone Hyperresorption. Dr. Schulman has no identified conflicts of interest.

Dr. Paritosh Suman reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Suman has no identified conflicts of interest.

Dr. Aaron I. Vinik reports that he has received speaker honoraria and consultant fees from Pamlab, Inc., consultant fees from Isis Pharmaceuticals, Inc. and NeuroMetrix, Inc., and research grant support for his role as Principal Investigator from Impeto Medical, Intarcia Therapeutics, Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi, ViroMed Laboratories, Inc., and VeroScience. He also reports that his presentation will include discussion of investigational or unlabeled uses of alpha lipoic for somatic and autonomic neuropathy; topiramate for painful and small fiber neuropathy; and methylcobolamin, methylfolate and pyridoxal phosphate for symptomatic neuropathy and patients on metformin with low B12 levels <450 pg.  Dr. Vinik has an identified conflict of interest and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Sunday Case Presentation Faculty Disclosures

Dr. Jason Calligas reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Calligas has no identified conflicts of interest.

Dr. Priya Dedhia reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Dedhia has no identified conflicts of interest.

Mr. Eric Finnesgard reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Mr. Finnesgard has no identified conflicts of interest.

Dr. Jessica Folek reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Folek has no identified conflicts of interest.

Dr. Shelby Holt reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Holt has no identified conflicts of interest.

Dr. Vikram Krishnamurthy reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Krishnamurthy has no identified conflicts of interest.

Dr. Cortney Lee reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lee has no identified conflicts of interest.

Dr. Janice Pasieka reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Pasieka has no identified conflicts of interest.

Dr. Latha Pasupuleti reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Pasupuleti has no identified conflicts of interest.

Dr. Eden Payabyab reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Payabyab has no identified conflicts of interest.

Dr. Alexander Shifrin reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Shifrin has no identified conflicts of interest.

Dr. Aida Taye reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Taye has no identified conflicts of interest.

Accreditation Statement

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 37.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.